Drug intelligence / Profile preview

MEG301

Development stage: Preclinical
Lead developer: Medley Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

MEG301 is an early-stage antibody-drug conjugate (ADC) being developed by Medley Therapeutics (formerly YAP Therapeutics) for the treatment of solid tumors. It is a component of the company's Advanced Biologics Platform, which focuses on fibrosis and oncology. While the specific target antigen and cytotoxic payload have not been publicly disclosed, the candidate is designed to utilize the ADC modality to provide targeted delivery of therapeutic agents to tumor cells. As of early 2024, MEG301 remains in the discovery phase of development.

Beyond the preview

Go deeper on MEG301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEG301.

Explore the full profile